GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal ...
GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults ...
GSK (NYSE:GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that its RSV (respiratory syncytial virus) vaccine, Arexvy, is associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results